Echinacea and colds: the short answer
Echinacea has not been proven to shorten an established cold. For prevention, a small effect remains possible, on the order of a 10–20% reduction in relative risk, with no certainty that it makes a noticeable difference. These are the conclusions of the Cochrane review, which remains the most rigorous synthesis available on the subject.
The main problem is not a lack of studies. There are dozens. It is that “echinacea” does not refer to one product, but to a range of plants, plant parts and extracts with little in common. A positive trial on one extract does not validate the bottle next to it.
For most healthy adults, echinacea is therefore not a priority purchase. Some people should avoid it altogether: those allergic to Asteraceae and those whose immune systems are already dysregulated or affected by treatment.
Why “echinacea” does not really exist
Three species share the shelves: Echinacea purpurea, the most studied, Echinacea angustifolia and Echinacea pallida. Depending on the manufacturer, the above-ground parts, the root or both are used, as freshly pressed juice, an alcoholic extract, dried powder or tablets.
The Cochrane review by Karsch-Völk and colleagues, published in 2014, makes this clear in its introduction: most consumers and doctors are unaware that these products differ substantially in composition. The authors did not pool the results in their main analysis, because the preparations tested were so heterogeneous.
Compounds thought to be active, such as alkylamides, caffeic acid derivatives and polysaccharides, vary by species, harvested part and solvent. A 2026 review devoted to E. purpurea concludes that it should be regarded as a source of chemically defined preparations, not as a uniform therapeutic substance.
The immunomodulatory and antiviral effects described in these studies come mainly from cell and animal research. They provide a biological hypothesis, not proof that your cold will be shorter. Winter marketing is happy to skip that distinction. This is Mitochondria Marketing: using a real biological mechanism to sell a product whose benefit has not been demonstrated.
Treatment: the cold runs its course
Cochrane included 24 double-blind trials with 4,631 participants. Of the seven treatment trials reporting cold duration, only one showed a significant effect of echinacea compared with placebo. The number of withdrawals due to adverse effects did not differ significantly between groups.
The largest publicly funded trial points in the same direction. In 2010, Barrett and colleagues recruited 719 people aged 12 to 80 at the start of a cold, with funding from the US National Institutes of Health. Participants received the equivalent of 10.2 g of dried root on the first day, then 5.1 g per day for four days.
The result: 6.34 days of cold symptoms with blinded echinacea treatment, versus 6.87 days with placebo. The 0.53-day difference was not significant (95% CI: -1.25 to 0.19). Overall severity showed a favorable trend, also not significant. The authors conclude that this formulation, at this dose, does not substantially change the course of a cold.
The most tightly controlled trial is even less encouraging. In 2005, Turner and colleagues exposed 399 volunteers to a rhinovirus under controlled conditions, with treatment taken preventively or at the time of inoculation. None of the three root extracts of E. angustifolia tested changed the infection rate or symptom severity.
The 2019 meta-analysis by David and Cunningham confirms this: a difference in duration of -0.45 days, with an interval ranging from -1.85 to +0.94 days. In other words, no demonstrated effect on duration.
Prevention: a weak signal and a contradiction
Prevention is where the evidence gets interesting. In the Cochrane review, none of the 12 prevention comparisons, taken individually, found a significant difference in the number of people who had at least one cold. But almost all their trends point in the same direction, and a post hoc pooled analysis suggests a 10–20% relative risk reduction.
The authors remain cautious: this pooled analysis was not planned initially, and the clinical relevance of such an effect is debatable. David and Cunningham found a figure of the same order, with a relative risk of 0.78 (95% CI: 0.68 to 0.88), while also flagging a risk of selective publication of results.
The NCCIH, the US agency dedicated to complementary medicine, summarizes the situation in its November 2024 update: echinacea might slightly reduce the risk of catching a cold, and it is still unclear whether it can shorten one.
The large favorable trial, and who funded it
The argument manufacturers cite most often is the trial by Jawad and colleagues, published in 2012. Conducted at Cardiff University’s Common Cold Centre, it followed 755 healthy adults, with an average age of 23, for four months. They took drops of an alcoholic fresh-plant extract three times a day, equivalent to 2,400 mg of extract daily, and 4,000 mg during colds.
In the intention-to-treat population, the placebo group accumulated 188 cold episodes and 850 days of symptoms, versus 149 episodes and 672 days in the echinacea group. Infections with certain enveloped viruses, such as influenza viruses or coronaviruses, were less frequent: 24 versus 47.
These figures deserve attention, with two caveats. The product tested came from a Swiss manufacturer, and the paper’s corresponding author is affiliated with that same manufacturer. Also, some of the main analyses included only participants who followed the protocol, and the authors themselves emphasize that the effect increased with adherence. The most consistent participants are not necessarily like the others, which opens the door to selection bias.
The contradiction to know about before buying
Here is the hidden Toll of prevention: its real cost in time, money and constraints. The only large favorable prevention trial required three doses a day for four months. Yet the European Medicines Agency’s European monograph limits the use of fresh-plant juice from E. purpurea to 10 days, for both prevention and treatment.
This framework does not say that taking it for four months is dangerous. It says that recognized use in Europe is based on short courses, and that the safety of prolonged use in everyone has not been established to the same standard. The “all winter” promise therefore does not match any approved use.
Table: what the main trials show
| Study | Population | Preparation | Main result |
|---|---|---|---|
| Cochrane 2014 | 24 trials, 4,631 participants | Various single-herb preparations | Treatment: 1 of 7 trials positive for duration. Prevention: 10–20% lower relative risk, post hoc analysis |
| Barrett 2010 | 719 adults and adolescents with colds | Echinacea root, 5 days | 0.53 days shorter, not significant |
| Turner 2005 | 399 volunteers exposed to a rhinovirus | 3 root extracts of E. angustifolia | No effect on infection or symptoms |
| Jawad 2012 | 755 healthy adults, 4 months | Fresh-plant extract of E. purpurea | 149 episodes versus 188, product and author linked to the manufacturer |
| Taylor 2003 | 407 children aged 2 to 11 | E. purpurea, up to 10 days per infection | No effect, more rashes |
This table does not compare products with one another. Above all, it shows that the result depends on the preparation, when it is taken and who conducted the trial.
The meta-analysis that promised 58% fewer colds
You will come across this figure on packaging and sales websites. It comes from a meta-analysis by Shah and colleagues, published in 2007 in The Lancet Infectious Diseases, which reported a 58% reduction in cold risk and a duration 1.4 days shorter.
This analysis pooled 14 studies with very different products and methods, with substantial statistical heterogeneity: the trials were not telling the same story. Seven years later, Cochrane, which included only single-herb preparations tested against placebo in double-blind trials and declined to pool everything, found nothing comparable.
Another meta-analysis, published by Schapowal and colleagues in 2015, reports a reduction in the risk of recurrent infections of around one-third (RR 0.649) across six selected trials. One of its authors is also a co-author of the Jawad trial. This is not proof of error, but a reason not to read these figures as independent of the studies they synthesize.
Safety: rare does not mean harmless
Over a short course, echinacea is generally well tolerated in adults. Cochrane found no significant difference in adverse effects, although it noted a trend toward more withdrawals due to adverse effects with echinacea in prevention trials. A safety meta-analysis published in 2026, covering 48 studies and 10,115 participants, found no more adverse effects than in the control groups.
These averages hide a rare and serious risk: allergy. The European monograph lists rashes, hives, itching and facial swelling, as well as cases of severe reactions, including Stevens-Johnson syndrome, angioedema, bronchospasm and anaphylactic shock. Their frequency is unknown. The risk is higher in people with atopy.
Who should avoid it or seek advice
The European monograph lists several situations in which echinacea is contraindicated or not recommended:
- An allergy to echinacea or another plant in the Asteraceae family, such as ragweed, chamomile, arnica or dandelion, is a contraindication.
- Its use is not recommended in people with autoimmune diseases, immune deficiencies, immunosuppressive treatments or white blood cell disorders. The text states that an association with autoimmune diseases cannot be ruled out.
- People with atopy should consult a doctor before taking it because of the risk of a severe allergic reaction.
- Because of insufficient data, use during pregnancy and breastfeeding is not recommended without medical advice.
- Use under age 12 is not recommended because of insufficient data.
Alcoholic extracts contain ethanol, which matters for people who need to avoid it. As for interactions, the monograph reports none, but the NCCIH notes conflicting data on drugs metabolized by the liver and theoretical reasons for caution with immunosuppressants and caffeine. The guide to supplement interactions helps you sort things out if you take several products.
In children, the trial that dampened enthusiasm
In 2003, Taylor and colleagues published a trial in JAMA involving 407 children aged 2 to 11, covering 707 upper respiratory tract infections. Echinacea did not shorten symptoms, with a median duration of 9 days in both groups. However, a rash occurred during 7.1% of infections treated with echinacea, versus 2.7% with placebo.
A 2025 systematic review of five pediatric trials is more optimistic about prevention, but flags problems with randomization, blinding and selective publication. For a child, advice from a doctor or pharmacist comes before any course of treatment.
If you still want to try it
The evidence does not justify recommending it. If you insist on trying it, the approach most consistent with the European framework remains short and measured:
- Choose a preparation of E. purpurea that clearly states the species, plant part and extract type, rather than a ten-ingredient winter blend.
- Follow the dose on the packaging, and stop after no more than 10 days.
- Note the date of the first symptoms and how they develop, without expecting a dramatic effect: according to the NHS, a cold generally improves within one to two weeks, with or without echinacea.
- Stop immediately if you develop a rash, itching, swelling or difficulty breathing.
Blends combining echinacea, vitamin C, zinc, propolis and elderberry mainly feed the Pill Cupboard: the accumulation of supplements taken without knowing which one does what. If a blend seems to work, there is no way to know which ingredient is responsible, or which caused an adverse effect. For zinc, the article on zinc lozenges for colds details an equally shaky body of evidence.
Finally, a useful November reminder: cold weather does not cause a cold · FR. Viruses do, and measures that limit their transmission, such as handwashing, remain less marketable than a bottle, but better supported.





